Stimulant Involvement in Opioid OD Death Higher for Those in Physically Demanding Jobs
By Elana Gotkine HealthDay Reporter
TUESDAY, April 1, 2025 -- A higher percentage of individuals who have psychostimulant involvement in synthetic opioid overdose deaths tend to work in physically demanding occupations and industries, according to research published in the March 27 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Eric W. Lundstrom, Ph.D., from the CDC in Atlanta, and colleagues conducted an exploratory study to characterize patterns of stimulant co-involvement among U.S. residents aged 15 to 64 years, stratified by decedents' usual occupation and industry using data on overdose deaths involving synthetic opioids from the 2022 National Vital Statistics System.
The researchers found that 53.6 percent of 69,893 fatal synthetic opioid overdoses involved stimulants. The highest percentages of synthetic opioid overdose deaths co-involving psychostimulants with abuse potential (psychostimulants) occurred in occupation and industry groups that were typically physically demanding (e.g., construction and extraction occupations), while the highest percentages of cocaine co-involvement were seen in industries that were generally less physically strenuous (e.g., business and financial occupations).
"These hypothesis-generating findings warrant confirmation but point to a potential role for work-related substance use and overdose prevention interventions," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-04-02 06:00
Read more

- Oklahoma Now Reporting Measles Cases Related to Texas/New Mexico Outbreak
- People With Disabilities Often Feel Disrespected by Health Care Workers
- Low Birth Weight Kids Lag In School Readiness
- AAN: Over-the-Counter Pain Relivers Tied to Fewer Concussion Symptoms
- FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
- LGBTQ+-Affirming Care Lacking in U.S. Primary Care Clinics
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions